ArticleResearch square2025
An HLA Association With COVID-19 Vaccine Reactogenicity Correlates With Fewer SARS-CoV-2 Infections and Monocyte Activation.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
Vaccination against SARS-CoV-2 has been the most effective tool in mitigating the COVID-19 pandemic. However, some individuals experience side effects that cause distress and interfere with daily activities, which can limit vaccine uptake, with important public health implications. Here, we considered the impact of HLA variation on the propensity for mild side effects with COVID-19 vaccination. We examined variation in HLA-A, -B, -C, -DRB1, and -DQB1 for association with self-reported side effects in a large cohort of U.S. Euro-ancestry vaccinated individuals (N = 50,535) and confirmed results in an independent replication cohort (N = 4,575). We found that HLA-A*03:01 was significantly associated with systemic side effects (OR = 1.36, CI = 1.31-1.41, p = 6.79×10-57) and fewer breakthrough infections, and that this phenomenon is specific to the COVID-19 vaccine. Surprisingly, we observed limited activation of CD8+ T cells in HLA-A*03:01+ samples to the Spike-derived peptides, excluding them as a likely source of the reported vaccine side effects. Rather, examination of immune cell subsets, prior and after vaccination, points to a central role for monocytes in the production of IL-6 and IL-8, which significantly correlates with the reported severity of side effects in HLA-A*03:01+ donors. Meanwhile, the large, mostly naïve, and low-affinity population of Spike-specific CD8+ T cells likely contribute to an inflammatory milieu in HLA-A*03:01 carriers through weak binding to antigen presenting cells. This work sheds light on the mechanisms underlying HLA-mediated COVID-19 vaccine reactogenicity and associated reduction in infections, providing important new insights that may support efforts to optimize vaccine efficacy and promote broader public involvement in vaccination programs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.